ProQR Therapeutics (NASDAQ:PRQR) Cut to Hold at StockNews.com

StockNews.com lowered shares of ProQR Therapeutics (NASDAQ:PRQR) from a buy rating to a hold rating in a report published on Friday.

A number of other equities research analysts have also weighed in on PRQR. Chardan Capital reiterated a neutral rating and set a $2.00 price objective on shares of ProQR Therapeutics in a report on Friday, August 4th. HC Wainwright restated a buy rating and issued a $5.00 price target on shares of ProQR Therapeutics in a report on Monday, August 7th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of Moderate Buy and an average target price of $3.88.

ProQR Therapeutics Trading Down 4.3 %

Shares of PRQR opened at $1.54 on Friday. ProQR Therapeutics has a 1-year low of $0.72 and a 1-year high of $3.85. The company has a 50-day moving average of $1.59 and a 200 day moving average of $1.98. The firm has a market capitalization of $124.46 million, a price-to-earnings ratio of -2.11 and a beta of -0.02. The company has a debt-to-equity ratio of 0.07, a current ratio of 5.71 and a quick ratio of 5.71.

ProQR Therapeutics (NASDAQ:PRQR) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.01. ProQR Therapeutics had a negative net margin of 1,427.27% and a negative return on equity of 86.23%. The company had revenue of $1.31 million during the quarter, compared to analyst estimates of $2.77 million. On average, research analysts expect that ProQR Therapeutics will post -0.25 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of PRQR. EcoR1 Capital LLC bought a new position in shares of ProQR Therapeutics during the 1st quarter worth approximately $6,183,000. M28 Capital Management LP grew its position in ProQR Therapeutics by 90.7% during the 4th quarter. M28 Capital Management LP now owns 1,910,600 shares of the biopharmaceutical company’s stock worth $7,069,000 after purchasing an additional 908,800 shares during the last quarter. Renaissance Technologies LLC purchased a new stake in ProQR Therapeutics during the 1st quarter worth approximately $547,000. Marshall Wace LLP grew its position in ProQR Therapeutics by 472.8% during the 4th quarter. Marshall Wace LLP now owns 420,615 shares of the biopharmaceutical company’s stock worth $1,556,000 after purchasing an additional 347,185 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its position in ProQR Therapeutics by 37.8% during the 1st quarter. JPMorgan Chase & Co. now owns 977,794 shares of the biopharmaceutical company’s stock worth $885,000 after purchasing an additional 268,315 shares during the last quarter. Institutional investors own 26.15% of the company’s stock.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).